After being diagnosed with Stevens-Johnson Syndrome (SJS), many patients begin searching for the medication that may have triggered the reaction. That search often raises another question: Should the drug’s label have warned me that Stevens-Johnson Syndrome was possible?
Product labels are intended to help physicians and patients understand a drug’s known risks. When evidence links a medication to Stevens-Johnson Syndrome or its more severe form, Toxic Epidermal Necrolysis (TEN), manufacturers have an ongoing responsibility to monitor safety information and update product labeling when appropriate.
An SJS diagnosis due to a medication doesn’t automatically mean that the drug manufacturer is legally responsible. However, when a company knew or reasonably should have known about a significant risk and failed to provide an appropriate safety warning, an injured patient may have grounds for a pharmaceutical product liability claim.
When Can an Inadequate Drug Warning Lead to an SJS Lawsuit?
Prescription medications and many over-the-counter drugs undergo extensive testing before reaching the market. Even so, rare adverse reactions sometimes become apparent only after thousands—or even millions—of patients begin using a medication.
Federal regulations require manufacturers to continue monitoring the safety of their products after FDA approval. As new evidence becomes available, companies are generally expected to update product labeling so physicians and patients understand newly identified or better-defined risks.
Knowing the risks of SJS when taking a drug can be especially important because the earliest symptoms often resemble a common viral illness before progressing into a life-threatening medical emergency. Early recognition may allow patients to stop the suspected medication sooner and seek immediate medical care.
"People sometimes assume that if a medication caused Stevens-Johnson Syndrome, the drug manufacturer is automatically responsible," says Ashley Spires, a pharmaceutical and medical malpractice litigation attorney with Childers, Schlueter & Smith. "That's not necessarily how these cases are evaluated. The question is whether the company adequately warned physicians and patients based on what it knew or reasonably should have known about the medication's risks." A lot of times there are adequate warnings from the manufacturer, but the prescribing physician fails to warn the patient of those risks, or the medication is prescribed to a patient who does not need it and/or at too high a dose.
Depending on the circumstances, SJS lawsuits may allege that a manufacturer:
- Failed to adequately warn about the risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.
- Delayed updating the product label after new safety information became available.
- Failed to adequately communicate known risks to prescribing physicians.
- Minimized or omitted important safety information in prescribing information or marketing materials.
Spires says one of the first questions attorneys examine is how the scientific evidence evolved over time.
"We're looking at when evidence linking the medication to Stevens-Johnson Syndrome became available, what information was reported to regulators, when the product label changed, and whether stronger warnings might have affected treatment decisions," she explains.
Internal company documents, adverse event reports, scientific studies, regulatory communications, and expert testimony often become important evidence in answering those questions.
Does Every Medication That Can Cause SJS Have a Warning?
Although Stevens-Johnson Syndrome remains rare, medical researchers have linked the condition to numerous prescription and over-the-counter medications. Some drugs have included SJS or TEN warnings for many years, while others have received updated labeling as additional safety information became available after FDA approval.
The presence of an SJS warning label doesn't automatically prevent litigation. In some lawsuits, the dispute isn't whether the medication carried a warning, but whether it appeared soon enough, accurately reflected the available scientific evidence, or adequately communicated the seriousness of the risk.
Because drug safety information continues to evolve after a medication reaches the market, each case must be evaluated based on the scientific knowledge and regulatory information available at the relevant time.
How Do Attorneys Evaluate Stevens-Johnson Syndrome Lawsuits?
Not every case of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis (SJS/TEN) results in a lawsuit. Some cases focus on whether a pharmaceutical manufacturer adequately warned physicians and patients about a medication's known or reasonably knowable risks. Others examine whether healthcare providers met the accepted standard of care by prescribing the medication appropriately, counseling the patient adequately and/or recognizing early symptoms, making a timely diagnosis, discontinuing the suspected medication, or providing appropriate treatment. In certain situations, both product liability and medical malpractice claims may arise from the same illness.
Determining whether legal action is appropriate requires far more than identifying the medication involved. Stevens-Johnson Syndrome attorneys handling these cases often work with physicians, pharmacologists, regulatory specialists, and other experts to review medical records, prescription history, FDA labeling, scientific literature, and adverse event reports. Together, this information helps establish what was known about the medication at the time it was prescribed, whether the drug likely caused the reaction, and whether physicians and patients received the information they needed to make informed treatment decisions.
"Every Stevens-Johnson Syndrome case deserves a careful review," says Spires. "Our job is to understand what happened, evaluate the available medical and regulatory evidence, and help families determine whether legal action may be appropriate and, if so, who claims should be made against."
